Most Read Articles
12 Jun 2018
Percutaneous coronary intervention (PCI) is a safe procedure to perform on obese and morbidly obese patients, a recent study has shown.
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

4 days ago
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
4 days ago
Use of quetiapine among critically ill patients rarely leads to corrected QT (QTc) interval prolongation, reports a new study.

Proton pump inhibitors exert no effect on acute MI risk

04 Dec 2017

Proton pump inhibitors do not appear to contribute to an increase in the risk of acute myocardial infarction (MI) compared with histamine-2 receptor antagonists (H2RAs), a study has shown.

Researchers followed more than 5 million new users of prescription PPIs and H2RAs for the development of MI. Median follow-up time was 60 days for patients with commercial insurance and 96 days for those with Medicare Supplemental insurance. Kaplan-Meier methods were applied to estimate the risk of MI at 3, 12 and 36 months after treatment initiation.

Results revealed the 12-month weighted risk of MI to be low overall, with approximately 2 cases per 1,000 among patients in commercial plans and 8 per 1,000 among patients in Medicare Supplemental plans.

When the risk difference (RD) was analysed, no significant difference in MI risk was seen between patients who started PPIs vs H2RAs for the first 12 months, either in the commercial population (weighted RD per 1,000, –0.08; 95 percent CI, –0.51 to 0.36) or the Medicare Supplemental population (weighted RD per 1000, –0.45;–1.53 to 0.58).

The present data indicate that physicians and patients should not avoid starting a PPI because of concerns related to MI risk, according to researchers.

The mechanism responsible for the effect of PPIs on MI is hypothesized to involve the altered vascular reactivity, as the drugs have been reported to inhibit dimethylarginine dimethylaminohydrolase. This leads to the blockade of vascular nitric oxide synthase activity and enhanced contractivity with loss of normal relaxation. [Gastroenterology 2015;149:830–833]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
12 Jun 2018
Percutaneous coronary intervention (PCI) is a safe procedure to perform on obese and morbidly obese patients, a recent study has shown.
Roshini Claire Anthony, 11 Jun 2018

Patients who received a combination of ticagrelor plus aspirin within 24 hours of undergoing coronary artery bypass grafting (CABG) had significantly improved saphenous vein graft patency rates 1 year post-procedure compared with those who only received aspirin, according to findings of the DACAB* trial.

4 days ago
Higher activity of plasma xanthine oxidase appears to be linked to insulin resistance and liver dysfunction among type 2 diabetes mellitus (T2DM) patients with metabolic syndrome (MetS), according to a recent Japan study.
4 days ago
Use of quetiapine among critically ill patients rarely leads to corrected QT (QTc) interval prolongation, reports a new study.